John V. Heymach, MD
Physician-scientist specializing in thoracic oncology and translational cancer research, with expertise in targeted therapies and immunotherapy; discusses VEGF–PD-1 bispecifics, tarlatimab, and phase 3 clinical data during the episode.
Best podcasts with John V. Heymach, MD
Ranked by the Snipd community
Feb 26, 2026 • 28min
S16 Ep11: Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data
John V. Heymach, MD, PhD, a thoracic oncology physician-scientist, and Anne S. Tsao, MD, MBA, a medical oncologist focused on thoracic immunotherapy, discuss bispecific antibodies. They cover PD-1/CTLA-4 platforms, VEGF–PD-1 mechanisms and trial data, and DLL3-directed T-cell engagers like tarlatimab. Conversation also touches on safety management and potential roles in thoracic cancers.
